Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial
Authors:
Open Access
- 24 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1177539
Abstract
Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-resistant. Based on these results, the company plans to conduct a phase 2a clinical trial to determine the safety and efficacy of HSG4112 in overweight and obese patients. Methods: A 16-week randomised, double-blind, placebo-controlled, parallel-group trial will be conducted at five large hospitals in South Korea to assess the safety and efficacy of HSG4112 in overweight and obese patients. Participants who meet the inclusion/exclusion criteria will be assigned a subject number and randomly assigned to one of the four treatment groups (one group receiving a placebo) in a 1:1:1:1 ratio. The study’s primary outcome will be to monitor the change in body weight (kg) from baseline to the end of treatment while monitoring safety and tolerability. Discussion: This trial will evaluate the efficacy and safety of HSG4112 in overweight and obese adults. Upon proving the safety and effectiveness of the newly developed mechanism, it might significantly improve the perception of the product among medical personnel and obese patients. Furthermore, it may aid in managing chronic conditions that require long-term treatment.Trial registration:ClinicalTrials.gov, identifier [NCT05197556].Keywords
This publication has 13 references indexed in Scilit:
- Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated ReviewThe World Journal of Men's Health, 2021
- The effectiveness of the low energy diet in overweight and obese adults.2016
- Latest approaches for the treatment of obesityExpert Opinion on Drug Discovery, 2015
- Diseases and disorders associated with excess body weight.2011
- A linear exponent AR(1) family of correlation structuresStatistics in Medicine, 2010
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009
- Statistical tests with accurate size and power for balanced linear mixed modelsStatistics in Medicine, 2007
- Analysis of multivariate repeated measures data with a Kronecker product structured covariance matrixJournal of Applied Statistics, 2001
- Power Calculations for General Linear Multivariate Models Including Repeated Measures ApplicationsJournal of the American Statistical Association, 1992
- Approximate Power for Repeated-Measures ANOVA Lacking SphericityJournal of the American Statistical Association, 1989